Should You Buy Novo Nordisk A/S (NVO) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Hold
Latest Price
60.330
1 Day change
-4.07%
52 Week Range
93.800
Analysis Updated At
2026/01/26
Novo Nordisk A/S (NVO) is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are positive catalysts such as strong demand for the Wegovy weight loss pill and hedge fund buying, the financial performance shows a significant decline in net income and EPS. Additionally, the class action lawsuit and potential competition from generics pose risks. The technical indicators and options data do not suggest a strong entry point currently.
Technical Analysis
The MACD histogram is positive at 0.365, indicating a bullish trend, but it is contracting, suggesting momentum may be slowing. RSI is at 67.435, which is neutral and not overbought or oversold. Moving averages are converging, indicating no clear trend. Key resistance is at 63.195, with support at 60.189.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Technical Summary
Sell
5
Buy
6
Positive Catalysts
Strong market acceptance of the oral Wegovy pill with over 18,410 prescriptions in the first week. Hedge funds are increasing their positions, with a 112.57% increase in buying over the last quarter.
Neutral/Negative Catalysts
A class action lawsuit alleging collusion with Teva to block generic versions of Victoza. Decline in market share of GLP-1 drugs and upcoming competition from generics. Financial metrics such as net income and EPS have significantly declined YoY.
Financial Performance
In Q3 2025, revenue increased by 11.81% YoY to $11.74 billion. However, net income dropped by 22.07% YoY to $3.13 billion, and EPS fell by 22.22% YoY to 0.7. Gross margin also declined by 9.53% YoY to 76.12.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Mixed ratings from analysts. Goldman Sachs raised the price target to DKK 436 with a Buy rating, citing positive momentum from the Wegovy pill. However, Barclays and JPMorgan lowered their price targets, and Argus downgraded the stock to Hold, citing declining market share and clinical trial setbacks.
Wall Street analysts forecast NVO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVO is 54.67 USD with a low forecast of 42 USD and a high forecast of 70 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast NVO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVO is 54.67 USD with a low forecast of 42 USD and a high forecast of 70 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 62.890
Low
42
Averages
54.67
High
70
Current: 62.890
Low
42
Averages
54.67
High
70
Citi
Neutral
initiated
DKK 400
AI Analysis
2026-01-27
New
Reason
Citi
Price Target
DKK 400
AI Analysis
2026-01-27
New
initiated
Neutral
Reason
Citi initiated coverage of Novo Nordisk with a Neutral rating and DKK 400 price target. The firm views the stock's valuation as appropriate at current share levels.
Goldman Sachs
Buy
maintain
2026-01-22
Reason
Goldman Sachs
Price Target
2026-01-22
maintain
Buy
Reason
Goldman Sachs raised the firm's price target on Novo Nordisk to DKK 436 from DKK 352 and keeps a Buy rating on the shares. The firm believes investor focus in the first half of 2026 will be the launch for Novo's Wegovy pill. The weight loss pill should contribute to positive earnings momentum in the near term, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NVO
